18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

by Ralf S. Eschbach, Philipp M. Kazmierczak, Maurice M. Heimer, Andrei Todica, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Georg Keinrath, Olga Solyanik, Jessica Olivier, Wolfgang G. Kunz, Maximilian F. Reiser, Peter Bartenstein, Jens Ricke, Clemens C. Cyran
Published 2018-01-01